Agios Pharmaceuticals Inc [AGIO] stock is trading at $30.21, up 2.30%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AGIO shares have gain 3.25% over the last week, with a monthly amount drifted -0.10%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on February 03, 2023, and set its price target to $41. On November 17, 2022, upgrade upgraded it’s rating to Neutral and revised its price target to $32 on the stock. SVB Leerink upgraded its rating to a Outperform but stick to its price target of $33 on July 27, 2022. BofA Securities initiated its recommendation with a Buy and recommended $54 as its price target on December 03, 2021. Goldman downgraded its rating to Sell for this stock on July 30, 2021, and downed its price target to $39. In a note dated July 01, 2021, Raymond James initiated an Mkt Perform rating.
Agios Pharmaceuticals Inc [AGIO] stock has fluctuated between $19.80 and $35.50 over the past year. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. Agios Pharmaceuticals Inc [NASDAQ: AGIO] shares were valued at $30.21 at the most recent close of the market. An investor can expect a potential return of 45.65% based on the average AGIO price forecast.
Analyzing the AGIO fundamentals
Agios Pharmaceuticals Inc [NASDAQ:AGIO] reported sales of 26.82M for the trailing twelve months, which represents a growth of 64.80%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -14.6%, Pretax Profit Margin comes in at -13.13%, and Net Profit Margin reading is -12.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.37 and Total Capital is -0.45. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.51 points at the first support level, and at 28.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.90, and for the 2nd resistance point, it is at 31.59.
Agios Pharmaceuticals Inc [AGIO] reported earnings per share of -$1.72 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.65/share, meaning a difference of $-0.07 and a surprise factor of -4.20%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$1.64 per share as compared to estimates of -$1.7 per share, a difference of $0.06 representing a surprise of 3.50%.
Ratios To Look Out For
For context, Agios Pharmaceuticals Inc’s Current Ratio is 12.27. Further, the Quick Ratio stands at 11.99, while the Cash Ratio is 1.3. Considering the valuation of this stock, the price to sales ratio is 63.29, the price to book ratio is 2.08.
Transactions by insiders
Recent insider trading involved FOUSE JACQUALYN A, Director, that happened on Apr 10 ’24 when 7791.0 shares were sold. Director, Foster-Cheek Kaye I completed a deal on Mar 07 ’24 to sell 1285.0 shares. Meanwhile, Director Foster-Cheek Kaye I sold 4415.0 shares on Mar 06 ’24.
